Goldman Sachs Group, Inc. (The) Analysts Give Sanofi SA (EPA:SAN) a €82.00 Price Target
A number of other research analysts also recently weighed in on the company. J P Morgan Chase & Co restated a neutral rating on shares of Sanofi SA in a research note on Wednesday. Credit Suisse Group set a €95.00 ($110.47) price target on Sanofi SA and gave the company a buy rating in a research note on Tuesday, July 4th. Jefferies Group LLC set a €90.00 ($104.65) price target on Sanofi SA and gave the company a neutral rating in a research note on Friday, June 16th. UBS AG set a €82.00 ($95.35) price target on Sanofi SA and gave the company a neutral rating in a research note on Wednesday, June 14th. Finally, Morgan Stanley set a €91.00 ($105.81) price target on Sanofi SA and gave the company a buy rating in a research note on Tuesday, June 6th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and five have given a buy rating to the company’s stock. Sanofi SA currently has a consensus rating of Hold and an average target price of €88.00 ($102.33).
Shares of Sanofi SA (EPA SAN) opened at 81.59 on Wednesday. Sanofi SA has a 52 week low of €62.50 and a 52 week high of €92.97. The company has a market cap of €103.03 billion and a PE ratio of 11.29. The company has a 50 day moving average price of €25.48 and a 200 day moving average price of €25.74.
WARNING: “Goldman Sachs Group, Inc. (The) Analysts Give Sanofi SA (EPA:SAN) a €82.00 Price Target” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.watchlistnews.com/goldman-sachs-group-inc-the-analysts-give-sanofi-sa-epasan-a-82-00-price-target/1461928.html.
Sanofi SA Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi SA and related companies with Analyst Ratings Network's FREE daily email newsletter.